In a study initiated in mid-2018 (NCT03606486), the University of Washington developed a minimally invasive test to detect ovarian cancer through screening cervix pap smear samples for tumor-associated mutations in TP53 (i.e., the most common mutated gene in ovarian cancer). This evidence concerns the gene TP53 and neoplasm.